# Validate Smart Breath Analyzer as Screening Tool for Diabetic, Hepatic, Renal, Lung, and Other Metabolic Disorders

> **NCT07646015** · — · COMPLETED · sponsor: **Respyr** · enrollment: 3000 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Liver Diseases
- Kidney Diseases
- Lung Diseases
- Metabolic Diseases
- Healthy Volunteers

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07646015
- **Lead sponsor:** Respyr
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-03
- **Primary completion:** 2023-10-03
- **Final completion:** 2023-10-05
- **Target enrollment:** 3000 (ACTUAL)
- **Last updated:** 2026-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07646015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07646015, "Validate Smart Breath Analyzer as Screening Tool for Diabetic, Hepatic, Renal, Lung, and Other Metabolic Disorders". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07646015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*